Alignment Healthcare Inc
For the period ended Sep 30, 2024. Filed Oct 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 29, 2024
ALHC$7.67+5.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating Activities: | ||
| Net loss | $(97,007) | $(100,942) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Provision for credit loss | 123 | 91 |
| Loss (gain) on right of use assets | 135 | (289) |
| Gain on sale of property and equipment | (8) | — |
| Depreciation and amortization | 20,254 | 15,807 |
| Amortization-investment discount | (2,084) | (3,349) |
| Amortization-debt issuance costs | 978 | 1,037 |
| Equity-based compensation | 54,896 | 51,183 |
| Non-cash lease expense | 1,360 | 1,653 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (19,226) | (12,724) |
| Prepaid expenses and other current assets | (8,809) | (3,771) |
| Other assets | 77 | (119) |
| Medical expenses payable | 91,726 | 33,299 |
| Accounts payable and accrued expenses | 2,835 | (4,613) |
| Deferred premium revenue | (116) | 146,034 |
| Accrued compensation | (161) | 7,604 |
| Lease liabilities | (1,492) | (2,622) |
| Net cash provided by operating activities | 43,481 | 128,279 |
| Investing Activities: | ||
| Purchase of investments | (75,524) | (281,582) |
| Sale of property and equipment | 14 | — |
| Maturities of investments | 152,755 | 160,735 |
| Acquisition of property and equipment | (32,134) | (25,398) |
| Net cash provided by (used in) investing activities | 45,111 | (146,245) |
| Financing Activities: | ||
| Proceeds from long-term debt | 50,000 | — |
| Debt issuance costs | (512) | — |
| Payment of employment taxes related to release of restricted stock | (350) | — |
| Contributions from noncontrolling interest holders | 15 | 60 |
| Net cash provided by financing activities | 49,153 | 60 |
| Net increase (decrease) in cash | 137,745 | (17,906) |
| Cash, cash equivalents and restricted cash at beginning of period | 204,954 | 411,299 |
| Cash, cash equivalents and restricted cash at end of period | $342,699 | $393,393 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $15,602 | $13,943 |
| Supplemental non-cash investing and financing activities: | ||
| Acquisition of property in accounts payable | $112 | $117 |
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total above:
| September 30, 2024 | September 30, 2023 | |
|---|---|---|
| Cash and cash equivalents | $340,300 | $391,643 |
| Restricted cash in other assets | 2,399 | 1,750 |
| Total | $342,699 | $393,393 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.